Wee1 Inhibitor AZD1775 Combined with Cisplatin Potentiates Anticancer Activity against Gastric Cancer by Increasing DNA Damage and Cell Apoptosis

Dual PI3K/mTOR inhibitor BEZ235 as a promising therapeutic strategy against paclitaxel-resistant gastric cancer via targeting PI3K/Akt/mTOR pathway

(2018) Dongshao Chen et al.   Cell Death & Disease

Development of a quantitative pharmacodynamic assay for apoptosis in fixed tumor tissue and its application in distinguishing cytotoxic drug−induced DNA double strand breaks from DNA double strand breaks associated with apoptosis

(2018) Angie B. Dull et al.   Oncotarget

Upregulation of WEE1 is a potential prognostic biomarker for patients with colorectal cancer

(2017) Xiao-Chuan Ge et al.   Oncology Letters

Upregulated WEE1 protects endothelial cells of colorectal cancer liver metastases

(2017) Peter J. Webster et al.   Oncotarget

A WEE1 Inhibitor Analog of AZD1775 Maintains Synergy with Cisplatin and Demonstrates Reduced Single-Agent Cytotoxicity in Medulloblastoma Cells

(2016) Christopher J. Matheson et al.   ACS Chemical Biology

Cancer statistics in China, 2015

(2016) Wanqing Chen et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Cytokinetic effects of Wee1 disruption in pancreatic cancer

(2016) Qing Chang et al.   CELL CYCLE

miR-520 promotes DNA-damage-induced trophoblast cell apoptosis by targeting PARP1 in recurrent spontaneous abortion (RSA)

(2016) Xiujuan Dong et al.   GYNECOLOGICAL ENDOCRINOLOGY

Phase I Study Evaluating WEE1 Inhibitor AZD1775 As Monotherapy and in Combination With Gemcitabine, Cisplatin, or Carboplatin in Patients With Advanced Solid Tumors

(2016) Suzanne Leijen et al.   JOURNAL OF CLINICAL ONCOLOGY

Expression and prognostic value of the WEE1 kinase in gliomas

(2016) Darija Music et al.   JOURNAL OF NEURO-ONCOLOGY

Targeting WEE1 Kinase in Cancer

(2016) Christopher J. Matheson et al.   TRENDS IN PHARMACOLOGICAL SCIENCES

Wee1 inhibition potentiates Wip1-dependent p53-negative tumor cell death during chemotherapy

(2016) V Clausse et al.   Cell Death & Disease

Targeting the WEE1 kinase as a molecular targeted therapy for gastric cancer

(2016) Hye-Young Kim et al.   Oncotarget

Dual PI3K/mTOR inhibitor BEZ235 exerts extensive antitumor activity in HER2-positive gastric cancer

(2015) Yan Zhu et al.   BMC CANCER

Synergistic antitumor interactions between MK-1775 and panobinostat in preclinical models of pancreatic cancer

(2015) Guan Wang et al.   CANCER LETTERS

Phase I Study of Single-Agent AZD1775 (MK-1775), a Wee1 Kinase Inhibitor, in Patients With Refractory Solid Tumors

(2015) Khanh Do et al.   JOURNAL OF CLINICAL ONCOLOGY

A novel bisindole-PBD conjugate causes DNA damage induced apoptosis via inhibition of DNA repair pathway

(2014) Pranjal Sarma et al.   CANCER BIOLOGY & THERAPY

The role of DNA repair pathways in cisplatin resistant lung cancer

(2014) Shane O’Grady et al.   CANCER TREATMENT REVIEWS

CHK It Out! Blocking WEE Kinase Routs TP53 Mutant Cancer

(2014) J. E. Bauman et al.   CLINICAL CANCER RESEARCH

Cisplatin in cancer therapy: Molecular mechanisms of action

(2014) Shaloam Dasari et al.   EUROPEAN JOURNAL OF PHARMACOLOGY

Synergistic Therapeutic Effect of Cisplatin and Phosphatidylinositol 3-Kinase (PI3K) Inhibitors in Cancer Growth and Metastasis ofBrca1Mutant Tumors

(2014) Athanassios Vassilopoulos et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Integrated genomic analysis identifies the mitotic checkpoint kinase WEE1 as a novel therapeutic target in medulloblastoma

(2014) Peter S Harris et al.   Molecular Cancer

Wee-1 Kinase Inhibition Overcomes Cisplatin Resistance Associated with High-Risk TP53 Mutations in Head and Neck Cancer through Mitotic Arrest Followed by Senescence

(2014) A. A. Osman et al.   MOLECULAR CANCER THERAPEUTICS

The predominant role of apoptosis in γH2AX formation induced by aneugens is useful for distinguishing aneugens from clastogens

(2014) Asako Harada et al.   MUTATION RESEARCH-GENETIC TOXICOLOGY AND ENVIRONMENTAL MUTAGENESIS

Cisplatin targets the stromal cell-derived factor-1-CXC chemokine receptor type 4 axis to suppress metastasis and invasion of ovarian cancer-initiating cells

(2014) Zhi-hua Yu et al.   TUMOR BIOLOGY

Improving the Efficacy of Chemoradiation with Targeted Agents

(2014) M. A. Morgan et al.   Cancer Discovery

The essential comet assay: a comprehensive guide to measuring DNA damage and repair

(2013) Amaya Azqueta et al.   ARCHIVES OF TOXICOLOGY

High expression of wee1 is associated with malignancy in vulvar squamous cell carcinoma patients

(2013) Gry Irene Magnussen et al.   BMC CANCER

Inhibition of Wee1 Sensitizes Cancer Cells to Antimetabolite Chemotherapeutics In Vitro and In Vivo, Independent of p53 Functionality

(2013) A. A. Van Linden et al.   MOLECULAR CANCER THERAPEUTICS

Preclinical Evaluation of the WEE1 Inhibitor MK-1775 as Single-Agent Anticancer Therapy

(2013) A. D. Guertin et al.   MOLECULAR CANCER THERAPEUTICS

Wee1 Inhibition by MK-1775 Leads to Tumor Inhibition and Enhances Efficacy of Gemcitabine in Human Sarcomas

(2013) Jenny M. Kreahling et al.   PLoS One

Forced activation of Cdk1 via wee1 inhibition impairs homologous recombination

(2012) M Krajewska et al.   ONCOGENE

High Expression of Wee1 Is Associated with Poor Disease-Free Survival in Malignant Melanoma: Potential for Targeted Therapy

(2012) Gry Irene Magnussen et al.   PLoS One

MK-1775, a Potent Wee1 Inhibitor, Synergizes with Gemcitabine to Achieve Tumor Regressions, Selectively in p53-Deficient Pancreatic Cancer Xenografts

(2011) N. V. Rajeshkumar et al.   CLINICAL CANCER RESEARCH

WEE1 Kinase Targeting Combined with DNA-Damaging Cancer Therapy Catalyzes Mitotic Catastrophe

(2011) P. C. De Witt Hamer et al.   CLINICAL CANCER RESEARCH

MK1775, a Selective Wee1 Inhibitor, Shows Single-Agent Antitumor Activity against Sarcoma Cells

(2011) J. M. Kreahling et al.   MOLECULAR CANCER THERAPEUTICS

MK-1775, a small molecule Wee1 inhibitor, enhances anti-tumor efficacy of various DNA-damaging agents, including 5-fluorouracil

(2010) Hiroshi Hirai et al.   CANCER BIOLOGY & THERAPY

In Silico Analysis of Kinase Expression Identifies WEE1 as a Gatekeeper against Mitotic Catastrophe in Glioblastoma

(2010) Shahryar E. Mir et al.   CANCER CELL

Advanced gastric cancer – Slow but steady progress

(2010) Derek G. Power et al.   CANCER TREATMENT REVIEWS

Identification of WEE1 as a potential molecular target in cancer cells by RNAi screening of the human tyrosine kinome

(2009) Lyndsay M. Murrow et al.   BREAST CANCER RESEARCH AND TREATMENT

Discovery of gene expression-based pharmacodynamic biomarker for a p53 context-specific anti-tumor drug Wee1 inhibitor

(2009) Shinji Mizuarai et al.   Molecular Cancer

Small-molecule inhibition of Wee1 kinase by MK-1775 selectively sensitizes p53-deficient tumor cells to DNA-damaging agents

(2009) H. Hirai et al.   MOLECULAR CANCER THERAPEUTICS

Integrated Functional, Gene Expression and Genomic Analysis for the Identification of Cancer Targets

(2009) Elizabeth Iorns et al.   PLoS One